Date:			4/25/2023		
You	ır Name:		Bettina Mittendorfer		
Manuscript Title:			Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity		
Mai	nuscript Number (if k	(nown):	169541-INS-CMED-TR-2		
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub			ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For e	/interest, it is preferable that you do so.	
-	t medication is not m	-		acturers of antinypertensive medication, even in	
	em #1 below, report ne for disclosure is th			rithout time limit. For all other items, the time	
			l entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	NIH gradung University	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection,	
	article processing charges, etc.) No time limit for this item.	DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Founda	574 (Washington University Digestive te Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular te Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins thropic Trust.	management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Click the tab key to add additional rows.	
	charges, etc.) No time limit for	DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Founda	1574 (Washington University Digestive the Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular the Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins	the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Click the tab key to add additional rows.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:		-	4/25/2023		
Your Name:		-	Brandon Kayser		
Manuscript Title:			$oxed{Heterogeneity}$ in the effect of marked weight loss on metabolic function in women with obesity $oxed{}$		
Ma	nuscript Number (if k	(nown):	169541-INS-CMED-TR-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doubt			ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For o	/interest, it is preferable that you do so.	
-	t medication is not m	-	· · · · · · · · · · · · · · · · · · ·	acturers of untillypercensive medication, even in	
	em #1 below, report ne for disclosure is th			rithout time limit. For all other items, the time	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH gra Univers Center Univers DK052 Diseas TR002 Clinica HL130 Diseas grants Associa Founda	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30 574 (Washington University Digestive e Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular e Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins hropic Trust.	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	NIH gra Univers Center Univers DK052 Diseas TR002 Clinica HL130 Diseas grants Associa Founda	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30 574 (Washington University Digestive e Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular e Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins	and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:			4/25/2023		
Your Name:			Mihoko Yoshino		
Manuscript Title:			Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity		
Mar	nuscript Number (if k	nown):	169541-INS-CMED-TR-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma			ited" means any relation with for-profit or n	es/interests listed below that are related to the ot-for-profit third parties whose interests may be ent to transparency and does not necessarily //interest, it is preferable that you do so.	
epid		nsion, you		example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	em #1 below, report ane for disclosure is the		•	vithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision	NIH gra	ants P30 DK056341 (Washington	The payments were made to the institution	
	of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Center University DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Founda	sity Nutrition and Obesity Research c), P30 DK020579 (Washington sity Diabetes Research Center), P30 2574 (Washington University Digestive se Research Center), and UL1 2345 (Washington University Institute of I and Translational Sciences), T32 2357 (Obesity and Cardiovascular se Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins thropic Trust.	and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	
	medical writing, article processing charges, etc.) No time limit for	Center University DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Founda	c), P30 DK020579 (Washington sity Diabetes Research Center), P30 1574 (Washington University Digestive se Research Center), and UL1 1545 (Washington University Institute of I and Translational Sciences), T32 1557 (Obesity and Cardiovascular se Postdoctoral Training Program), from the American Diabetes 1546 ation (2019-011), and the Atkins	and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:			4/25/2023		
You	r Name:		Jun Yoshino		
Manuscript Title:			Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity		
Mar	nuscript Number (if k	(nown):	169541-INS-CMED-TR-2		
content of your manuscript. "Rela affected by the content of the ma			nted" means any relation with for-profit or n nuscript. Disclosure represents a commitme t about whether to list a relationship/activity		
epic		nsion, you		example, if your manuscript pertains to the facturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th			vithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH gr. Univer Center Univer DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Found	ants P30 DK056341 (Washington sity Nutrition and Obesity Research P), P30 DK020579 (Washington sity Diabetes Research Center), P30 P574 (Washington University Digestive Research Center), and UL1 P345 (Washington University Institute of P357 (Obesity and Cardiovascular Research Center) P577 (Obesity and Cardiovascular Research Center) P778 (P578 P787 (P578 P787 P787 P787 P787 P787 P787 P787	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	
			Time frame: past 36 month	is	
2	Grants or contracts from	[⊠] No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:			4/25/2023		
You	r Name:		Jeramie Watrous		
Manuscript Title:			Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity		
Mar	nuscript Number (if k	(nown):	169541-INS-CMED-TR-2		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doub." The author's relationships/activiti epidemiology of hypertension, yo that medication is not mentioned.		ript. "Rela of the mar e in doubt os/activitie nsion, you entioned all suppor	ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity es/interests should be defined broadly. For easy a should declare all relationships with manuf in the manuscript.	/interest, it is preferable that you do so.	
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH gra Univers Center Univers DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Founda	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30 574 (Washington University Digestive e Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular e Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins hropic Trust.	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	
				Click the tab key to add additional rows.	
			Time frame: past 36 month	,	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:		_	4/25/2023			
Your	r Name:	. <u>-</u>	Mohit Jain			
Manuscript Title:		-	Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity			
Man	uscript Number (if k	known):	169541-INS-CMED-TR-2			
content of your manuscript. "Rela affected by the content of the ma			ted" means any relation with for-profit or no nuscript. Disclosure represents a commitme about whether to list a relationship/activity	/interest, it is preferable that you do so.		
epid		ension, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if		
	em #1 below, report ne for disclosure is th			rithout time limit. For all other items, the time		
			entities with whom you have this	Specifications/Comments (e.g., if payments were		
		relations	hip or indicate none (add rows as needed)	made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	University Center, University DK052. Disease TR002: Clinical HL1303 Disease grants Association Foundations.	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30 574 (Washington University Digestive e Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular e Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins hropic Trust.	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Click the tab key to add additional rows.		
			Time frame: past 36 month	s		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ No	one			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
10	Leadership or fiduciary role in other board,		

			ons/Comments (e.g., if payments were ou or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea		t to the following statement to indicate your agreement: answered every question and have not altered the wording of any	of the questions on this form

Date:			4/25/2023			
You	ır Name:		J. Christopher Eagon			
Manuscript Title:			Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity			
Mai	nuscript Number (if l	known):	169541-INS-CMED-TR-2			
con affe	tent of your manuscrected by the content of	ript. "Rela of the ma				
epic	· ·	nsion, you	· · · · · · · · · · · · · · · · · · ·	example, if your manuscript pertains to the acturers of antihypertensive medication, even if		
	em #1 below, report ne for disclosure is th		·	ithout time limit. For all other items, the time		
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. No time limit for this for this item.		[□] No	one			
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Univer Center Univer DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Found	ants P30 DK056341 (Washington sity Nutrition and Obesity Research P), P30 DK020579 (Washington sity Diabetes Research Center), P30 P574 (Washington University Digestive Research Center), and UL1 P5345 (Washington University Institute of I and Translational Sciences), T32 P5357 (Obesity and Cardiovascular Re Postdoctoral Training Program), P576 from the American Diabetes P576 ation (1-18-ICTS-119), the Longer Life P576 ation (2019-011), and the Atkins P576 thropic Trust.	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.		
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Univer Center Univer DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Found	sity Nutrition and Obesity Research 1), P30 DK020579 (Washington University Digestive 1), P30 DK020579 (Washington University Institute of 1), P30 DK020579 (Washington University Institute of 1), P31 DK020579 (Washington University Institute of 2), P32 DK020579 (Washington University Institute of 2), P32 DK020579 (Washington 2), P33 DK020579 (Washington 2), P34	and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the		
	funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Univer Center Univer DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Found	sity Nutrition and Obesity Research 1), P30 DK020579 (Washington University Digestive 1), P30 DK020579 (Washington University Institute of 1), P30 DK020579 (Washington University Institute of 1), P31 DK020579 (Washington University Institute of 2), P32 DK020579 (Washington University Institute of 2), P32 DK020579 (Washington 2), P33 DK020579 (Washington 2), P34	and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:		4/25/2023			
You	r Name:		Bruce W. Patterson		
Mar	nuscript Title:		Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity		
Mar	nuscript Number (if k	(nown):	169541-INS-CMED-T	R-2	
content of your manuscript. "Rela affected by the content of the ma			ited" means any relation	on with for-profit or no presents a commitme	es/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so.
epic		nsion, you	u should declare all rel		example, if your manuscript pertains to the acturers of antihypertensive medication, even if
	em #1 below, report ne for disclosure is th			ed in this manuscript w	ithout time limit. For all other items, the time
			l entities with whom y ship or indicate none (Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Si	nce the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH gr. Univer Center Univer DK052 Diseas TR002 Clinica HL130 Diseas grants Associ Found	ants P30 DK056341 sity Nutrition and Ob), P30 DK020579 (Wasity Diabetes Resear 574 (Washington Ur ise Research Center), 345 (Washington Ur I and Translational S 357 (Obesity and Case Postdoctoral Train from the American E ation (1-18-ICTS-119 ation (2019-011), and thropic Trust.	esity Research /ashington rch Center), P30 niversity Digestive and UL1 niversity Institute of sciences), T32 ardiovascular ing Program), Diabetes 9), the Longer Life	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
			Time	e frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).		one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None ■	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Dat	e:	-	4/25/2023			
Your Name:		-	Samuel Klein			
Manuscript Title:		-	Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity			
Ma	nuscript Number (if k	known):	169541-INS-CMED-TR-2			
con affe indi	the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the ontent of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be ffected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily idicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the pidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if					
tha	t medication is not m	entioned i	in the manuscript.			
	em #1 below, report me for disclosure is th		· · · · · · · · · · · · · · · · · · ·	ithout time limit. For all other items, the time		
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	NIH gra Univers Center Univers DK052 Diseas TR002 Clinica HL130 Diseas grants Associa Founda	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30 574 (Washington University Digestive e Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular e Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins hropic Trust.	The payments were made to the institution and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	NIH gra Univers Center Univers DK052 Diseas TR002 Clinica HL130 Diseas grants Associa Founda	ants P30 DK056341 (Washington sity Nutrition and Obesity Research), P30 DK020579 (Washington sity Diabetes Research Center), P30 574 (Washington University Digestive e Research Center), and UL1 345 (Washington University Institute of I and Translational Sciences), T32 357 (Obesity and Cardiovascular e Postdoctoral Training Program), from the American Diabetes ation (1-18-ICTS-119), the Longer Life ation (2019-011), and the Atkins	and the funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None	
13	Other financial or non-financial interests	⊠ None	
Plea 🖂		t to the following statement to indicate your agreeme answered every question and have not altered the wo	

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1 and 2
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	13-17
Setting	5	Describe the setting, locations, and relevant dates, including periods of	13-17
C		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of	13-17
•		selection of participants. Describe methods of follow-up	
		Case-control study—Give the eligibility criteria, and the sources and methods	
		of case ascertainment and control selection. Give the rationale for the choice of	
		cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and	
		methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of	
		exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and the	
		number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	13-17
		effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	13-17
measurement		assessment (measurement). Describe comparability of assessment methods if	
		there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	13-17
Quantition (variable)		describe which groupings were chosen and why	10 17
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	17
		confounding	-,
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	N/A
		Case-control study—If applicable, explain how matching of cases and controls	1071
		was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking	
		account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
ontinued on next page		(E) Describe any sensitivity analyses	1 N/ /A

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	N/A
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and	Table
data		information on exposures and potential confounders	1 and
			pages
			6-9
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time	N/A
		Case-control study—Report numbers in each exposure category, or summary measures of	
		exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their	
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for	
		and why they were included	
		(b) Report category boundaries when continuous variables were categorized	yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a	
		meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity	N/A
		analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or	9-13
		imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	9-13
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	9-13
Other information	on —		
Funding	22	Give the source of funding and the role of the funders for the present study and, if	3
-		applicable, for the original study on which the present article is based	

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.